|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RG, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adam R, De Gramont A, Figueras J, Guthrie
A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P,
Rubbia-Brandt L, et al: The oncosurgery approach to managing liver
metastases from colorectal cancer: A multidisciplinary
international consensus. Oncologist. 17:1225–1239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jones RP, Stättner S, Sutton P, Dunne DF,
McWhirter D, Fenwick SW, Malik HZ and Poston GJ: Controversies in
the oncosurgical management of liver limited stage IV colorectal
cancer. Surg Oncol. 23:53–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
NCCN: NCCN Clinical Practice Guidelines in
Oncology. Colon Cancer. Version 2. 2017, http://www.nccn.orgFebruary 24–2018
|
|
6
|
Yoshino T, Arnold D, Taniguchi H,
Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh
KH, et al: Pan-Asian adapted ESMO consensus guidelines for the
management of patients with metastatic colorectal cancer: A
JSMO-ESMO initiative endorsed by CSCO KACO, MOS, SSO and TOS. Ann
Oncol. 29:44–70. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Venook A, Niedzwiecki D, Lenz H, Mahoney
M, Innocenti F, O'Neil B, Shaw J, Polite B, Hochster H, Goldberg R,
et al: CALGB/SWOG 80405: Analysis of patients undergoing surgery as
part of treatment strategy. Ann Oncol. 25 Suppl 4:S1–S41. 2014.
View Article : Google Scholar
|
|
9
|
Recondo G Jr, Díaz-Cantón E, de la Vega M,
Greco M, Recondo G Sr and Valsecchi ME: Advances and new
perspectives in the treatment of metastatic colon cancer. World J
Gastrointest Oncol. 6:211–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamada Y, Denda T, Gamoh M, Iwanaga I,
Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi
K, et al: S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or
CapeOX plus bevacizumab as first-line treatment in patients with
metastatic colorectal cancer (TRICOLORE): A randomized, open-label,
phase III, noninferiority trial. Ann Oncol. 29:624–631. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolmark N, Wieand HS, Rockette HE, Fisher
B, Glass A, Lawrence W, Lerner H, Cruz AB, Volk H, Shibata H, et
al: The prognostic significance of tumor location and bowel
obstruction in Dukes B and C colorectal cancer. Findings from the
NSABP clinical trials. Ann Surg. 198:743–752. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Loupakis F, Yang D, Yau L, Feng S,
Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ,
et al: Primary tumor location as a prognostic factor in metastatic
colorectal cancer. J Natl Cancer Inst. 107(pii):
dju4272015.PubMed/NCBI
|
|
13
|
Petrelli F, Tomasello G, Borgonovo K,
Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G and Barni S:
Prognostic survival associated with left-sided vs right-sided colon
cancer: A systematic review and meta-analysis. JAMA Oncol. Oct
27–2016.(Epub ahead of print).
|
|
14
|
Boeckx N, Janssens K, Van Camp G,
Rasschaert M, Papadimitriou K, Peeters M and Op de Beeck K: The
predictive value of primary tumor location in patients with
metastatic colorectal cancer: A systematic review. Crit Rev Oncol
Hematol. 121:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boisen MK, Johansen JS, Dehlendorff C,
Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard
LS, Holländer NH, et al: Primary tumor location and bevacizumab
effectiveness in patients with metastatic colorectal cancer. Ann
Oncol. 24:2554–2559. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brulé SY, Jonker DJ, Karapetis CS,
O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D,
Zalcberg JR, et al: Location of colon cancer (right-sided versus
left-sided) as a prognostic factor and a predictor of benefit from
cetuximab in NCIC CO.17. Eur J Cancer. 51:1405–1414. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen H, Yang J, Huang Q, Jiang MJ, Tan YN,
Fu JF, Zhu LZ, Fang XF and Yuan Y: Different treatment strategies
and molecular features between right-sided and left-sided colon
cancers. World J Gastroenterol. 21:6470–6478. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holch JW, Ricard I, Stintzing S, Modest DP
and Heinemann V: The relevance of primary tumour location in
patients with metastatic colorectal cancer: A meta-analysis of
first-line clinical trials. Eur J Cancer. 70:87–98. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA
Oncol. Oct 10–2016.(Epub ahead of print).
|
|
20
|
Aljehani MA, Morgan JW, Guthrie LA, Jabo
B, Ramadan M, Bahjri K, Lum SS, Selleck M, Reeves ME, Garberoglio C
and Senthil M: Association of primary tumor site with mortality in
patients receiving bevacizumab and cetuximab for metastatic
colorectal cancer. JAMA Surg. 153:60–67. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishihara S, Murono K, Sasaki K, Yasuda K,
Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Hata K, et
al: Impact of primary tumor location on postoperative recurrence
and subsequent prognosis in nonmetastatic colon cancers: A
multicenter retrospective study using a propensity score analysis.
Ann Surg. 267:917–921. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita S, Brudvik KW, Kopetz SE, Maru
D, Clarke CN, Passot G, Conrad C, Chun YS, Aloia TA and Vauthey JN:
Embryonic origin of primary colon cancer predicts pathologic
response and survival in patients undergoing resection for colon
cancer liver metastases. Ann Surg. 267:514–520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kobayashi H, Tanisaka K, Doi O, Kodama K,
Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, et
al: An in vitro chemosensitivity test for solid tumors using
collagen gel droplet embedded cultures. Int J Oncol. 11:449–455.
1997.PubMed/NCBI
|
|
24
|
Kobayashi H, Higashiyama M, Minamigawa K,
Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination
of in vitro chemosensitivity test using collagen droplet culture
method with colorimetric endpoint quantification. Jpn J Cancer Res.
92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi H: Development of a new in vitro
chemosensitivity test using collagen gel droplet embedded culture
and image analysis for clinical usefulness. Recent Results Cancer
Res. 161:48–61. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Corrie PG: Cytotoxic chemotherapy:
Clinical aspects. Medicine. 36:24–28. 2008. View Article : Google Scholar
|
|
27
|
Ochiai T, Nishimura K, Watanabe T,
Kitajima M, Hashiguchi T, Nakatani A, Marusasa T, Muraki A, Nagaoka
I and Futagawa S: Leucovorin and fluorouracil plus oxaliplatin or
leucovorin and fluorouracil plus irinotecan as individualized
first-line therapy based on a drug sensitivity test. Exp Ther Med.
1:325–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ochiai T, Nishimura K, Watanabe T,
Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T,
Kishine K, et al: Individualized chemotherapy for colorectal cancer
based on the collagen gel droplet-embedded drug sensitivity test.
Oncol Lett. 4:621–624. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ochiai T, Nishimura K, Watanabe T,
Kitajima M, Nakatani A, Nagayasu K, Naito S, Sato T, Kishine K, Abe
Y, et al: Impact of the individualization of the first-line
chemotherapy for advanced colorectal cancer based on collagen gel
droplet-embedded drug sensitivity test. Oncol Lett. 14:6045–6052.
2017.PubMed/NCBI
|
|
30
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer
G, et al: Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin
Oncol. 18:2938–2947. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J,
Alakl M, et al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: A multicentre randomized trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee MS, McGuffey EJ, Morris JS, Manyam G,
Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang
ZQ, et al: Association of CpG island methylator phenotype and
EREG/AREG methylation and expression in colorectal cancer. Br J
Cancer. 114:1352–1361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SE, Paik HY, Yoon H, Lee JE, Kim N and
Sung MK: Sex- and gender-specific disparities in colorectal cancer
risk. World J Gastroenterol. 21:5167–5175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sinicrope FA, Mahoney MR, Smyrk TC,
Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM,
Sargent DJ and Alberts SR: Prognostic impact of deficient DNA
mismatch repair in patients with stage III colon cancer from a
randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin
Oncol. 31:3664–3672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ochiai T, Nishimura K, Noguchi H, Kitajima
M, Watanabe T, Nagaoka I and Futagawa S: Prognotic impact of
orotate phosphoribosyl transferase among 5-fluorouracil metabolic
enzymes in resectable colorectal cancers treated by oral
5-fluorouracil-based adjuvant chemotherapy. Int J Cancer.
118:3084–3088. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ochiai T, Umeki M, Miyake H, Iida T,
Okumura M, Ohno K, Sakamoto M, Miyoshi N, Takahashi M, Tsumura H,
et al: Impact of 5-fluorouracil metabolizing enzymes on
chemotherapy in patients with resectable colorectal cancer. Oncol
Rep. 32:887–892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Minderman H, Conroy JM, O'Loughlin KL,
McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ and Baer MR: In
vitro and in vivo irinotecan-induced changes in expression profiles
of cell cycle and apoptosis-associated genes in acute myeloid
leukemia cells. Mol Cancer Ther. 4:885–900. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lévi F, Metzger G, Massari C and Milano G:
Oxaliplatin: Pharmacokinetics and chronopharmacological aspects.
Clin Pharmacokinet. 38:1–21. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fink D, Zheng H, Nebel S, Norris PS, Aebi
S, Lin TP, Nehmé A, Christen RD, Haas M, MacLeod CL and Howell SB:
In vitro and in vivo resistance to cisplatin in cells that have
lost DNA mismatch repair. Cancer Res. 57:1841–1845. 1997.PubMed/NCBI
|
|
42
|
Fink D, Nebel S, Aebi S, Zheng H, Cenm B,
Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair
in platinum drug resistance. Cancer Res. 56:4881–4886.
1996.PubMed/NCBI
|
|
43
|
Chaney SG, Campbell SL, Bassett E and Wu
Y: Recognition and processing of cisplatin- and oxaliplatin-DNA
adducts. Crit Rev Oncol Hematol. 53:3–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kiyonari S, Iimori M, Matsuoka K, Watanabe
S, Morikawa-Ichinose T, Miura D, Niimi S, Saeki H, Tokunaga E, Oki
E, et al: The 1,2-diaminocyclohexane carrier ligand in oxaliplatin
induces p53-dependent transcriptional repression of factors
involved in thymidylate biosynthesis. Mol Cancer Ther.
14:2332–2342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ramachandran S, Temple B, Alexandrova AN,
Chaney SG and Dokholyan NV: Recognition of platinum-DNA adducts by
HMGB1a. Biochemistry. 51:7608–7617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yoshida M, Ishiguro M, Ikejiri K,
Mochizuki I, Nakamoto Y, Kinugasa Y, Takagane A, Endo T, Shinozaki
H, Takii Y, et al: S-1 as adjuvant chemotherapy for stage III colon
cancer: A randomized phase III study (ACTS-CC trial). Ann Oncol.
25:1743–1749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
André T, de Gramont A, Vernerey D,
Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T,
Tabernero J, Van Laethem JL, et al: Adjuvant fluorouracil,
leucovorin, and oxaliplatin in stage II to III colon cancer:
Updated 10-year survival and outcomes according to BRAF mutation
and mismatch repair status of the MOSAIC study. J Clin Oncol.
33:4176–4187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hamaguchi T, Shimada Y, Mizusawa J,
Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Takiguchi N, Yatsuoka T,
Takii Y, et al: Capecitabine versus S-1 as adjuvant chemotherapy
for patients with stage III colorectal cancer (JCOG0910): An
open-label, non-inferiority, randomised, phase 3, multicentre
trial. Lancet Gastroenterol Hepatol. 3:47–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
